INTELLIA THERAPEUTICS

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 11月 2024 15:01:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

31 10月 2024 08:45:01 条件 NetDania Notify

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

31 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

30 10月 2024 08:45:22 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

29 10月 2024 10:48:28 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

24 10月 2024 08:46:04 条件 NetDania Notify

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24 10月 2024 07:01:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 10月 2024 08:45:05 条件 NetDania Notify

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

07 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 10月 2024 09:23:57 条件 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 10月 2024 15:01:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 10月 2024 08:45:08 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 10月 2024 08:45:32 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 10月 2024 12:25:49 条件 NetDania Notify

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 9月 2024 06:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

11 9月 2024 09:45:32 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 9月 2024 09:37:45 条件 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 9月 2024 15:30:00 条件 Nasdaq GlobeNewswire